🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Colo-rectal Cancer (dMMR/MSI-H CRC)

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer NCT07352280n/a1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites📍 Phoenix📍 San Diego📍 Tampa MOMA Therapeutics · Tests: MOMA-341, Irinotecan, Immunotherapy Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer NCT06903858Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM) NCT06353854n/a20 sites📍 Bayonne📍 Beauvais📍 Besançon Federation Francophone de Cancerologie Digestive Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients NCT06098560n/a2 sites📍 Beijing📍 Shanghai Geneplus-Beijing Co. Ltd. PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer NCT05236972Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Sintilimab, Oxaliplatin, capecitabine Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379Phase 1, Phase 28 sites📍 Beverly Hills📍 Glendale📍 Los Angeles Neonc Technologies, Inc. · Tests: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer NCT06520683Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Tislelizumab, Adjuvant chemotherapy Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors NCT07829081n/a3 sites📍 Basel📍 Biel📍 Lucerne University Hospital, Basel, Switzerland · Tests: Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers NCT05239546Phase 22 sites📍 Iowa City📍 Madison University of Iowa · Tests: Dostarlimab The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial. NCT06477991n/a1 site📍 Kunming Yunnan Cancer Hospital · Tests: Tireilizumab（PD-1 inhibitor） Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer NCT06698757Phase 21 site📍 Zheng'zhou Yugui Lian · Tests: Sintilimab Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424Phase 21 site📍 Pittsburgh Diwakar Davar · Tests: nivolumab, pembrolizumab Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) NCT07327489n/a8 sites📍 Fort Smith📍 Frederick📍 Springfield Elephas · Tests: Biopsy Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC NCT07003022Phase 21 site📍 Shanghai Fudan University · Tests: cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib… EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors NCT07262619Phase 1, Phase 245 sites📍 Los Angeles📍 Doral📍 Hialeah Eikon Therapeutics · Tests: EIK1005, pembrolizumab (KEYTRUDA® ) A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448Phase 239 sites📍 Phoenix📍 Los Angeles📍 Lone Tree Ono Pharmaceutical Co., Ltd. · Tests: ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors NCT07213609Phase 1, Phase 227 sites📍 Aurora📍 Detroit📍 Canton GlaxoSmithKline · Tests: GSK5460025 Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer NCT03926338Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Neoadjuvant toripalimab plus celecoxib for 6 cycles, Neoadjuvant toripalimab monotherapy for 6 cycles, Neoadjuvant tori… Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer NCT07412613Phase 31 site📍 Guangzhou Akeso · Tests: Cadonilimab (AK104), Oxaliplatin, Capecitabine, 5- Fluorouracil, Calcium Folinate
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy